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GUIDELINE
FOREWORD
Thyroid disease is a common clinical problem encountered by 
all healthcare practitioners. To date there have been no South 
African guidelines for the management of any aspect of thyroid 
disease. This guideline represents the first in a series of guidelines 
reviewing the management of various aspects of thyroid disease. 
Unless otherwise specified, this guideline pertains to the care of 
non-pregnant adults with hypothyroidism. 
Hypothyroidism is a common clinical problem encount-ered by 
all healthcare practitioners. Despite adequate treatment, some 
patients with hypothyroidism remain symptomatic prompting 
many healthcare practitioners to question the treatments used 
and the recommended treatment targets. In addition, frustrated 
patients often turn to alternative medical supplements in an 
attempt to improve their symptoms. This is the first South African 
guideline for the management of hypothyroidism in adults and 
represents a comprehensive review of the current literature in an 
attempt to provide evidence-based guidance for all healthcare 
practitioners regarding the many clinical aspects encountered 
when managing patients with hypothyroidism. This guideline 
is not intended to replace professional judgement, experience 
and appropriate referral. These guidelines are intended to inform 
general patterns of care that will enhance the management of 
patients with hypothyroidism. They reflect the best available 
evidence at the time, and practitioners are encouraged to 
keep updated with the latest information. Whilst care has been 
taken to ensure accuracy, SEMDSA/ Association of Clinical 
Endocrinologists of South Africa (ACE-SA, a subgroup of SEMDSA) 
assumes no responsibility for personal or other injury, loss or 
damage that may result from the information in this publication. 
The Guideline development process
The process we followed in developing the guideline was as 
follows:
1. The SEMDSA executive committee entrusted the guideline 
process to ACE-SA
2. The broad topic of the management of patients with thyroid 
disease was divided into smaller sections. ACE-SA then 
invited all endocrinologists who wanted to be involved in 
the guideline process to lead the guideline development for 
a specific section
3. A Guideline Meeting was held in Cape Town on 18th/19th 
October 2014. The following participants were invited to this 
meeting:
a. All members of ACE-SA who had indicated that they 
wanted to be involved in the guideline process
b. Representatives from the Department of Health
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c. Representatives from the Council of Medical Schemes
d. Representatives from Faculty of Consulting Physicians of 
South Africa, South African Society of Nuclear Medicine, 
Association of Surgeons of South Africa
e. Representatives from Medical Schemes
4. The meeting was funded using unrestricted educational 
grants from two pharmaceutical companies involved in 
the field of managing patients with hypothyroidism and 
hyperthyroidism. Two representatives from each company 
were allowed observer status at the meeting (i.e. they were 
not allowed to participate in the proceedings of the meeting).
5. At the Guideline Meeting, each endocrinologist was required 
to present the proposed guideline for their allocated section 
to the audience. The information presented was interrogated 
and amendments and additions were suggested. The 
discussions were evidence-based (see box 1), but where 
evidence was lacking, a consensus among participants was 
adopted (see box 2).
6. Two ACE-SA members recorded detailed minutes of the 
discussions and debates at the meeting.
7. After the Guideline Meeting, each section was rewritten 
according to an agreed format and included suggestions 
made at the Guideline Meeting.
8. A Writing Group was then convened in Cape Town on 
the 30th/31st May 2015. At this meeting each section was 
reviewed. The group decided that the guideline should be 
published in 4 separate sections: Management of Adult 
patients with Hypothyroidism, Management of Adult 
patients with Hyperthyroidism, Management of patients 
with a Thyroid Nodule and Management of Hypothyroidism 
and Hyperthyroidism in Pregnancy. 
9. The revised draft guideline for the management of 
hypothyroidism was then sent to all members of ACE-SA and 
other societies involved in the management of patients with 
hypothyroidism.
10. After receiving final comments, the guideline was amended 
as required and submitted for publication 
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INTRODUCTION
Hypothyroidism is defined as a condition where the thyroid 
gland is unable to make adequate thyroid hormone to meet the 
requirements of the peripheral tissues. In primary hypothyroidism 
the thyroid gland fails to produce sufficient quantities of thyroid 
hormone to maintain normal thyroid stimulating hormone (TSH) 
secretion. This failure of negative feedback results in elevated 
levels of TSH. In secondary hypothyroidism (1% of all cases of 
hypothyroidism), disease of either the hypothalamus or pituitary 
gland results in inadequate TSH production and therefore 
insufficient stimulation of structurally and functionally normal 
thyroid gland. In early secondary hypothyroidism the TSH 
may be normal but is biologically inactive with the hallmark of 
secondary hypothyroidism being a normal or low TSH and a low 
free thyroxine (fT4). This guideline provides 11 recommendations 
for the management of primary hypothyroidism, secondary 
hypothyroidism and sub-clinical hypothyroidism in adults (see 
Table 1).
Primary hypothyroidism
Iodine deficiency is the commonest cause of hypothyroidism 
worldwide.1 Voluntary salt iodisation was introduced in South 
Africa in 1954 but achieved minimal reduction in endemic goiter 
and hypothyroidism.2 Mandatory iodisation of table salt at 40-
60 ppm in 1995 dramatically improved the situation; a 1998 
survey showed that optimal iodine nutrition, determined by 
urinary iodine concentration (UIC) where iodine deficiency is 
defined as a UIC < 100 μg/L, was achieved nationally in seven 
of the nine provinces; with more than adequate iodine intake in 
two provinces. At that time, 86.4% of households used iodised 
salt and 62.4% used adequately iodised salt that contained 
more than 15 ppm of iodine, with low coverage rates (<50%) 
in the three northern provinces (Limpopo, Mpumalanga and 
North West).2 To maintain a sufficient iodine status, the World 
Health Organization (WHO), the United Nations Children’s Fund 
(UNICEF) and the International Council for Control of Iodine 
Deficiency Disorders (ICCIDD) recommend age dependent daily 
iodine intake: 90 μg for preschool children (0 to 59 months), 
120 μg for children (6 to12 years) and 150 μg for adults (above 
12 years). The recommendation for pregnant and lactating 
women has recently been increased to 250 μg per day.3 Box 1: Level of Evidence
IA Evidence from meta-analysis of randomised controlled trials
IB Evidence from at least one randomised controlled trial
IIA Evidence from at least one controlled study without 
randomisation
IIB Evidence from at least one other type of quasi-experimental study
III Evidence from non-experimental descriptive studies, such as 
comparative studies, correlation studies, and case-control studies
IV Evidence from expert committee reports or opinions or clinical 
experience of respected authorities or both
Box 2: Strength of recommendation
Weak Based on poor scientific data or consensus of the 
Guideline Panel
Moderate Based on weak scientific data or consensus of the 
Guideline Panel
Strong Based on robust scientific data or consensus of the 
Guideline Panel
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The National Health and Nutrition Examination Survey 
(NHANES III) studied an unselected U.S. population over age 12 
between 1988 and 1994 and quoted 0.3% prevalence for overt 
hypothyroidism.4 It is important to note that one has to have 
a high index of suspicion and at the same time recognise that 
many of the clinical features of hypothyroidism are non-specific. 
The severity of symptoms not only depends on the duration 
of the disease but also the rapidity with which it develops. 
Autoimmune thyroid disease may affect quality of life, even in 
euthyroid individuals.5,6
Subclinical hypothyroidism (SCH)
This condition is defined as a repeated serum TSH elevated above 
the normal range with a persistently normal free T4 and free T3 
which is stable over a period of weeks, occurring in the absence 
of hypothalamic-pituitary disease and no recent non-thyroidal 
illness. Population prevalence varies between 5 - 10%, depending 
on the cohort.4,7-9 Unfortunately, there is limited data on the 
prevalence of SCH in the general population in South Africa.10 
SCH should be considered in 2 categories: those with a TSH 
> 10 mIU/L and those with a TSH 4.0 - 10.0 mIU/L. It is important 
to differentiate between younger (< 65 years) and older patients 
(> 80-85 years) as the TSH increases with age and it is thought 
that a rising TSH may confer a physiological advantage. SCH is 
associated with increased coronary heart disease (CHD) risk 
including both CHD events and mortality from CHD. The risk 
of CHD events and CHD mortality increases with increasing 
TSH, particularly with TSH levels > 10.0 mIU/L. Consequently, 
there is little debate in the literature about treating patients 
with TSH levels persistently > 10.0 mIU/L.11-13 Treatment of 
patients with TSH levels 4.0 – 10 mIU/L is controversial as there 
are few randomized controlled trials to guide management of 
this group. Different aspects have been examined including 
recommendations for thyroxine therapy in individuals with a 
goitre, those with positive thyroid peroxidase antibodies (TPO 
Ab), those with an increased cardiovascular risk and in those 
Table I: Recommendations for the management of hypothyroidism









2 Treat patients with persistent elevations of the serum TSH level > 10.0 mIU/L as there is an increased risk 
of coronary heart disease (CHD) events and CHD mortality with increasing levels of TSH, particularly with 
TSH levels > 10.0mU/L 
1A Strong
3 Treatment of patients with persistent elevations of serum TSH 4.0–10 mIU/L is controversial. Treatment 
of patients with cardiovascular disease (CVD), increased risk for CVD, presence of thyroid peroxidase 




4 The serum TSH level should be used to monitor adequacy of thyroid hormone replacement and should 
be assessed 4-8 weeks after any dosage change and until the goal TSH is reached and maintained
IIA Strong
5 The serum TSH level target should be: 








6 Liothyronine (Tertroxin®) and other forms of thyroid hormone replacement should not be used routinely IA Strong
Elderly
7 Maintain a high index of suspicion for hypothyroidism in elderly patients (> 65 years) as they may lack the 
typical symptoms and signs
IV Strong
8 The serum TSH level is higher for elderly individuals (> 65 years) and a higher target  
TSH level on LT4 replacement therapy of 4.0-6.0 mIU/L may be appropriate in those  
> 65 years old
IV Strong
Secondary hypothyroidism
9 The serum TSH level should NOT be measured in the management of secondary hypothyroidism IV Strong
10 The serum fT4 level should be used to monitor adequacy of LT4 replacement therapy and should be 
assessed 4-8 weeks after any dosage change until the goal fT4 is reached and maintained
IIA Strong
11 The fT4 target should be maintained within the upper half of the reference range of a given laboratory IV Moderate
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with symptoms. The currently available data does not provide 
clear-cut benefit to all groups, hence a number of views exist and 
consensus panels are suggesting that the key determinant in this 
group of patients should be good clinical judgement.14,15 
Obese patients with SCH should be managed cautiously as 
TSH levels may increase with increasing obesity and revert to 
normal levels with weight loss such as occurs following gastric 
banding and gastric bypass.16,17 The AACE strongly recommends 
against thyroid hormone replacement for treatment of obesity in 
euthyroid patients.15 
The measurement of TPO Abs is advised by several professional 
societies and clinical endocrinologists as the presence of elevated 
TPO Ab titres helps predict progression to overt hypothyroidism. 
Many patients with chronic autoimmune thyroiditis may have 
a normal TSH; however, approximately 75% have elevated anti-
thyroid antibody titres including anti-thyroglobulin antibodies 
(Tg Ab), anti-thyroid peroxidase/anti-microsomal antibodies 
(TPO Ab) and TSH receptor antibodies. In the NHANES survey 
of a disease-free population, 10.4% of individuals tested 
positive for Tg Ab and 11.3% for TPO Ab.4 A positive TPO Ab 
test was significantly associated with the development of 
hypothyroidism, hence the recommendation for measurement 
of TPO Ab levels.14,18 TPO Abs are the most sensitive serologic test 
for thyroid autoimmunity in subclinical hypothyroidism.19 Serum 
concentrations wane with time and therefore repeated antibody 
measurements do not contribute to management of patients 
with SCH.20
Screening for SCH is not recommended as there is no consensus 
on the benefits of therapy.
Elderly patients
The prevalence of hypothyroidism (overt and subclinical) is 10% 
in men and 16% in women in the age group 65-74 years and 
increases to 16% and 21% respectively in subjects older than 
74 years.7 The main causes of hypothyroidism in older adults 
are autoimmune thyroiditis, postoperative hypothyroidism, and 
post-radioiodine hypothyroidism.21 Serum TSH levels increase 
with age in both males and females. This increase may result 
in values above the upper limit of the traditional reference 
range in elderly persons with normal thyroid function. The 
prevalence of positive anti-thyroid antibodies also increases with 
advancing age. TPO Abs and Tg Abs are positive in up to 20% 
of healthy elderly subjects. Importantly, the presence of thyroid 




a. Pharmacological agent: 
• L-thyroxine (LT4) monotherapy: considered the standard 
of care despite the absence of randomized clinical trials 
comparing LT4 to placebo. Withdrawal of LT4 leads to 
recurrence of the signs and symptoms of hypothyroidism. 
• Combination therapy: there is increasing evidence to suggest 
that the TSH level achieved by LT4 is unable to achieve 
adequate T3 levels in all tissues prompting some to suggest 
that combination therapy with LT4 and triiodothyronine 
would be preferable. However, multiple randomised-
controlled trials have shown conflicting results.22-27 In addition, 
multiple meta-analyses have suggested no clinical benefit of 
combination therapy concluding that monotherapy with LT4 
should remain the treatment of choice.28-30 There has also 
been a suggestion that perhaps treatment of hypothyroidism 
should be individualized with specific individuals possibly 
benefiting more from combination therapy.31 
• Desiccated thyroid extract (DTE): there is some evidence to 
suggest that treatment with DTE (animal-derived, porcine; 
contains T4 and T3) may be at least equivalent to LT4 in 
normalizing TSH levels and improving symptoms in some 
patients preferring therapy with DTE compared to LT4.32 
However, there is a lack of long-term studies proving 
the safety and efficacy of DTE compared to LT4, and the 
relative excess of T3 in these preparations often produces 
supraphysiological levels of T3 which have unknown long-
term consequences and which may produce symptoms.33
• Selenium: selenium is currently being investigated for its 
possible disease modifying effects in thyroid pathology, 
including autoimmune diseases. However, the data on the 
role of selenium supplementation in decreasing TPO Abs 
and decreasing the risk of hypothyroidism is conflicting. 
Some studies show a decrease in TPO Abs in auto-
immune thyroiditis and a decrease in risk of post-partum 
hypothyroidism in pregnant patients that have TPO Abs34,35 
while some studies show no affect.36-38 A meta-analysis 
showed a decrease in TPO Ab titres at 3 months with some 
improvement in mood and general well-being, however, 
the data is not sufficiently consistent to recommend routine 
selenium supplementation.39 
• Other formulations: there is no consistent data for 
the use of any other formulation for the treatment of 
hypothyroidism, including but not limited to L-tyrosine, 
Asian ginseng, bladderwrack, Capsaicin, Echinacea and 
3,5,3’-Triidothyroacetic acid. 
b. Target TSH level: For many years there has been debate 
on the target TSH range for treatment of patients 
with hypothyroidism. Recent studies have shown no 
clinical benefit of treating to low normal TSH ranges.40,41 
Consequently, the goal of treatment is to maintain the TSH 
level in the defined 3rd generation assay range for the specific 
pathology laboratory, but preferably at 0.5 – 3.0 mIU/L.
c. Factors affecting absorption of LT4: Food and a number 
of medications affect the absorption of LT4 (see Table II). 
Randomised-controlled studies show that taking LT4 60 
minutes before breakfast or 4 hours after the last meal of the 
day achieve the best absorption of LT4, but no data shows 
which of these options is superior.42,43
d. Initiating dose of LT4: Patients with minimal residual thyroid 
function or those that have had a total thyroidectomy usually 
require about 1.6 ug LT4/kg daily[44, 45]. Young healthy 
patients can be initiated with the full dose of LT4 whereas 
patients with cardiovascular disease should be initiated on 
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25 ug LT4 daily and healthy patients > 60 years old should 
be initiated on 50 ug LT4 daily.46 Dose adjustments may be 
required with ageing,47,48 weight loss and in pregnancy. In 
addition, those with subclinical hypothyroidism may require 
lower doses of LT4. 
Secondary hypothyroidism
There are multiple retrospective studies but only one randomized 
controlled trial (RCT). The RCT showed that using a LT4 dose 
of 1.6 µg/kg and maintaining the fT4 in the upper half of the 
reference range obtained the best reduction in symptoms of 
hypothyroidism.49 There are no longterm studies.
Subclinical hypothyroidism
Symptoms: The Colorado Thyroid Disease Prevalence Study, a 
questionnaire based study in 25,862 subjects, showed a small but 
significant difference in symptoms between euthyroid patients 
and those with SCH.7 There are a number of small studies looking 
at improvement of symptoms with thyroxine replacement which 
do not show any significant benefit. However, one randomised 
crossover study, using 100 µg LT4 or placebo in 100 subjects with 
a mean TSH of 6.6mIU/L showed a significant improvement in 
tiredness.50
Dyslipidaemia: Heterogeneous results were obtained in 
observational studies investigating the relationship between 
SCH and dyslipidaemia. Data from the Colorado Thyroid Disease 
Prevalence Study shows a positive relationship between TSH and 
dyslipidaemia, suggesting that there are already alterations in the 
lipid profile prior to the development of overt hypothyroidism.7 
The association of SCH with increasing levels of TC, low density 
lipoproteins (LDL) and triglycerides (TG) are greatest for TSH 
levels > 10.0 mIU/L.51 There is data showing improvement in 
various lipid parameters with treatment with LT4; however, lipid 
targets may not be achieved and lipid lowering therapy may still 
be required.52,53
Coronary heart disease: The Cleveland Clinic Preventative 
Cardiology Clinic showed that patients with CHD risk, < 65 
years and TSH elevation 6.1 - 10.0 mIU/L as well as > 10.0 mIU/L 
untreated with LT4 had a higher all-cause mortality.54 A recent 
analysis of 3 093 patients (40-70 years old) and 1 642 patients 
(over 70 years old) from the United Kingdom General Practitioner 
Research Database with a TSH level 5.01 - 10.0 mIU/L showed that 
treatment with LT4 reduced CHD event rates over the 7.6 years 
of follow-up but only in those that were 40-70 years old.54 There 
remains conflicting data on the risk of ischaemic heart disease 
(IHD) in patients with SCH. Some meta-analyses have shown an 
increased risk for IHD and cardiovascular mortality in patients 
< 65 years old13,55 and some have not.53 However, there are no 
RCTs with hard cardiac endpoints. Treatment with LT4 in patients 
with SCH who are < 65 years old should be considered. There is 
no data to suggest that this increases risk.54 There is also some 
data to suggest that patients > 65 years old with SCH are also at 
increased risk for IHD,56 although there is no data to suggest that 
treatment will decrease this risk.54 Not all studies have shown that 
age is a predictor of risk for IHD in patients with SCH and there 
is no robust data to suggest that treatment with LT4 reduces risk 
for IHD. 
Psychiatric illness: SCH affects declarative and working memory.57 
There is some evidence showing that treatment improves mood 
in younger patients. It is not unreasonable to consider treatment 
in patients with depression, bipolar mood disorder and cognitive 
dysfunction. The effect of SCH on cognition and mood in people 
> 65 years old is unclear.58 
Type 2 diabetes: There is a reduction in insulin sensitivity in 
patients with SCH and the possibility of worsening glycaemic 
control in patients with type 2 diabetes (T2DM). There is some 
evidence to show that treatment with LT4 improves insulin 
sensitivity.59 Therefore, consider treatment with LT4 in patients 
with T2DM and SCH. Review glycaemic control 3 months after 
thyroid targets are achieved to ascertain whether to continue 
therapy with LT4.
Elderly
Metabolism of thyroid hormone is altered in older people due 
to altered absorption, reductions in lean body mass and the 
use of numerous drugs for co-morbid conditions so that the 
response to replacement doses of levothyroxine should be 
monitored closely in individuals in this age group.60 In addition, 
elderly patients often lack the typical symptoms and clinical 
signs associated with hypothyroidism.61 The TSH level increases 
with age whereby 40% of people > 80 years old with no thyroid 
disease have a TSH level > 2.5 mIU/L and 14.5% have a TSH level 
> 4.5 mIU/L.62 This shows that older patients may have an elevated 
TSH as part of the normal ageing process and not due to thyroid 
dysfunction. Therefore, some suggest that age-specific reference 
ranges should be used when interpreting TSH levels but these 
have not been validated in the South African setting.
Table II: Factors affecting the absorption of LT4
• Bile acid sequestrants (cholestyramine, colestipol, colesevelam)
• Sucralfate
• Cation exchange resins (Kayexelate)
• Oral bisphosphonates
• Proton pump inhibitors
• Raloxifene
• Multivitamins (containing ferrous sulfate or calcium carbonate)
• Ferrous sulfate
• Phosphate binders (sevelamer, aluminum hydroxide)





• H2 receptor antagonists
• Dietary factors:
 - Ingestion with a meal
 - Grapefruit juice
 - Espresso coffee
 - High fibre diet
 - Soybean formula (infants)
 - Soy
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CLINICAL PRACTICE 
RECOMMENDATIONS (see Figure 1)
Primary Hypothyroidism: because primary hypothyroid-ism 
accounts for 99% of cases of hypothyroidism, the TSH level is 
an appropriate screening test. If the TSH is elevated, serum free 
Thyroxine (fT4) should be measured. Free T3 (fT3) and reverse T3 
(rT3) levels are not required for the diagnosis and management 
of patients with primary hypothyroidism or SCH. Thyroid 
antibodies are useful to confirm autoimmunity and should only 
be measured at the time of diagnosis. They play no role in the 
ongoing management of the patient and should therefore not 
be measured again.
Secondary hypothyroidism: if secondary hypothyroidism is 
suspected then fT4 levels should be measured as a screening test
TSH screening: there is no consensus about population 
screening for hypothyroidism:
• American Thyroid Association recommends that TSH be 
measured at age 35 years and every 5 years thereafter.63 
This is primarily based on the limited accuracy of clinical 
diagnosis. If only patients with clearly suggestive signs and 
symptoms were tested then many affected patients will 
remain undiagnosed.
• American Association of Clinical Endocrinologists suggests 
screening of older patients (age not specified), especially 
woman64
• The U.S. Preventive Services Task Force concluded that 
evidence is insufficient to recommend for or against routine 
screening for thyroid disease in adults.65
It is recommended that the TSH level should be measured in 
various clinical situations (see Box 3).
Treatment of patients with LT4
• All patients with primary hypothyroidism, secondary 
hypothyroidism and SCH (TSH > 10 mIU/L) should be treated 
with LT4 monotherapy.
• Initiate with full replacement doses of LT4 (1.6 µg/kg 
calculated on lean body mass) in young patients with overt 
primary or secondary hypothyroidism. Full replacement 
doses are generally not required in patients with SCH. In 
these patients 25 to 75 µg is usually sufficient for achieving 
euthyroid levels. Older patients (> 65 years old) or those 
with heart failure, ischaemic heart disease or arrhythmias 
should be initiated on lower doses (12.5 to 25 µg). In patients 
with secondary hypothyroidism, hypoadrenalism should be 
excluded first before starting treatment with LT4.
• Repeat TSH level every 4-8 weeks in patients with primary 
hypothyroidism or SCH. 
• Repeat fT4 every 4-8 weeks in patients with secondary 
hypothyroidism. There is no role for monitoring the TSH 
level in the management of patients with secondary 
hypothyroidism so this should not be measured.
• Aim for TSH levels within the normal range of a 3rd generation 
TSH assay for a specific pathology laboratory, but preferably 
0.5 – 3.0 mIU/L. In patients > 65 years old the TSH level should 
be maintained at 4.0 - 6.0 mIU/L .
• LT4 dose adjustment should generally be no higher than 12.5 
to 25 µg per day (either up or down) depending on the TSH 
level in primary hypothyroidism and fT4 level in secondary 
hypothyroidism. Serum TSH (primary hypothyroidism) and 
fT4 (secondary hypothyroidism) should be repeated every 
4-8 weeks until the goal is achieved. Thereafter, the TSH 
(primary hypothyroidism) or fT4 (secondary hypothyroidism) 
may be measured every 6-12 months.
• Dose requirements of LT4 may change under some 
circumstances such as pregnancy, weight loss or gain, 
addition of concomitant medications known to affect LT4 
requirements or absorption of LT4 (see Table II) and gastro-
intestinal disease.
• Excessive LT4 and iatrogenic hyperthyroidism should be 
avoided as it may lead to adverse outcomes such as atrial 
fibrillation, heart failure and osteoporosis.66-68 Under-
replacement should also be avoided as there may be a 
detrimental effect on the lipid profile and cardiovascular 
disease.52,69
•  Co-morbidities may be present in elderly patients and drugs 
often prescribed for these conditions may interfere with 
the absorption and metabolism of levothyroxine so more 
frequent monitoring of TSH levels is often required. 
• Once target TSH levels are achieved, the TSH level should 
be repeated at 6-12 monthly intervals. Once a decision has 
been made to continue lifelong therapy and the patient is 
clinically and biochemically stable on replacement therapy 
with LT4 then follow-up with a GP is suggested. 
• Once the patient is euthyroid then lipid levels should be 
checked. 
• The use of dessicated thyroid preparations and combination 
therapy is not advised.
Box 3: Suggested clinical situations in which TSH testing should be 
considered
• Symptomatic patients
• Autoimmune disease, such as type 1 diabetes 
• First-degree relative with autoimmune thyroid disease 
• History of neck radiation, radioactive iodine therapy and external 
beam radiotherapy for head and neck malignancies 
• Prior history of thyroid surgery or dysfunction
• Abnormal thyroid examination
• Psychiatric disorders 
• Patients taking amiodarone or lithium 
• Infertility and repeated miscarriages
• Growth retardation and delayed puberty 
• Other
 - Pregnant woman with risk factors
 - Genetic syndromes (e.g. Down’s syndrome, Turner syndrome)
 - Hyperprolactinaemia
 - Dyslipidemia
 - Heart failure
 - Chronic constipation
 - Dementia
 - Obesity
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Management of patients with SCH  
(TSH 4-10 mIU/L, normal fT4)
• If TPO Abs are positive then patients should be treated with 
LT4 as the presence of TPO Abs appears to confer greater risk 
of progression to overt hypothyroidism (4.3%/yr. vs 2.6%).8
• If TPO Abs are negative then it may be prudent to consider 
a trial of therapy in patients < 65 years old with: symptoms, 
pregnancy, psychiatric illness, dyslipidaemia, coronary heart 
disease or type 2 diabetes. 
Referral to a specialist
Referral to an endocrinologist or specialist physician should 
be considered in patients with hypothyroidism or SCH in the 
following clinical situations:
• Children
• Patients with poor control, for example lack of control after 
two dose adjustments
• Planning conception or pregnancy
• Infertility
• Cardiac disease
• Structural abnormalities of the thyroid gland such as nodules 
or a goitre
• Co-morbid endocrine disorders such as pituitary, adrenal or 
polyglandular auto-immune disorders
• Unusual thyroid results or unusual causes of hypothyroidism
• Psychiatric disorders
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